Linagliptin

A summary of the most common chemical descriptors (InChI Key and SMILES codes) for Linagliptin are summarized together with 3D and 2D structures and relevant physico-chemical properties.

What is the Linagliptin?

The molecule Linagliptin presents a molecular formula of C18H21NO5 and its IUPAC name is 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione.

Linagliptin is a molecule used as a medication to treat type 2 diabetes. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor..

Linagliptin was approved for medical use in the United States in 2011. It exists as a generic medication. In the United Kingdom it is marketed as Trajenta by Boehringer Ingelheim..

The most common adverse effects of linagliptin are upper respiratory tract infection, headache, and diarrhea. Linagliptin can cause low blood sugar levels. It is unclear if it is safe for use during pregnancy or breastfeeding..

Linagliptin is a white to yellowish powder that is soluble in water. It is a prodrug that is rapidly converted to its active metabolite, linagliptin carboxylic acid..

Linagliptin works by inhibiting DPP-4, an enzyme that breaks down GLP-1, a hormone that regulates blood sugar levels. By inhibiting DPP-4, linagliptin increases levels of GLP-1, which helps to lower blood sugar levels..

Linagliptin is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes..

Linagliptin is typically started at a dose of 5 mg once daily. The dose can be increased to 10 mg once daily if needed..

Linagliptin should be taken with meals..

Common side effects of linagliptin include upper respiratory tract infection, headache, and diarrhea..

Linagliptin can cause low blood sugar levels. It is unclear if it is safe for use during pregnancy or breastfeeding..

Linagliptin is a safe and effective medication for the treatment of type 2 diabetes..

3D structure

Cartesian coordinates

Geometry of Linagliptin in x, y and z coordinates (Å units) to copy/paste elsewhere. Generated with Open Babel software.

2D drawing

 

Linagliptin LUMAEVHDZXIGEP-MEDUHNTESA-N chemical compound 2D structure molecule svg
Linagliptin

 

Molecule descriptors

 
IUPAC name8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
InChI codeInChI=1S/C18H21NO5/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3/t11-,16+/m0/s1
InChI KeyLUMAEVHDZXIGEP-MEDUHNTESA-N
SMILESC[C@@H](Cc1ccc2c(c1)OCO2)NC[C@@H](O)c1ccc(O)c(O)c1

Other names (synonyms)

IUPAC nomenclature provides a standardized method for naming chemical compounds. Although this system is widely used in chemistry, many chemical compounds have also other names commonly used in different contexts. These synonyms can come from a variety of sources and are used for a variety of purposes.

One common source of synonyms for chemical compounds is the common or trivial names, assigned on the basis of appearance, properties, or origin of the molecule.

Another source of synonyms are historical or obsolete names employed in the past, however replaced nowadays by more modern or standardized names.

In addition to common and historical names, chemical compounds may also have synonyms that are specific to a particular field or industry.

  • (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • (R)-8-(3-Aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
  • (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione
  • (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
  • (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
  • 1-[(4-Methylquinazolin-2-yl)-methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine
  • 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine
  • 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine
  • 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)aminopiperidin-1-yl)xanthine
  • 1-[(4-methyl-quinazolin-2yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R) amino-piperidin-1-yl]-xanthine
  • 1233245-11-8
  • 1H-PURINE-2,6-DIONE, 8-((3R)-3-AMINO-1-PIPERIDINYL)-7-(2-BUTYNYL)-3,7-DIHYDRO-3-METHYL-1-((4-METHYL-2- QUINAZOLINYL)METHYL)-
  • 1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-
  • 270L120
  • 3X29ZEJ4R2
  • 668270-12-0
  • 8-((3R)-3-AMINOPIPERIDIN-1-YL)-7-(BUT-2-YN-1-YL)-3-METHYL-1-((4-METHYLQUINAZOLIN-2-YL)METHYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
  • 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
  • 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d
  • 8-[(3R)-3-Aminopiperidin-1-yl]-7-but-2-yn-1-yl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-d ione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
  • 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
  • 8-[(3r)-3-Aminopiperidin-1-Yl]-7-But-2-Yn-1-Yl-3-Methyl-1-[(4-Methylquinazolin-2-Yl)methyl]-3,7-Dihydro-1h-Purine-2,6-Dione
  • AB01563307_01
  • AB01563307_03
  • AC-8761
  • AMY8953
  • AS-35080
  • BCP02462
  • BCP9000854
  • BCPP000185
  • BDBM50228403
  • BI 1356
  • BI 1356 BS
  • BI-1356
  • BI-1356-BS
  • BI-1356BS
  • BL164627
  • BS 1356 BS
  • BS-1356-BS
  • C25H28N8O2
  • CCG-269463
  • CS-0637
  • D09566
  • DB08882
  • EX-A076
  • GLYXAMBI COMPONENT LINAGLIPTIN
  • GTPL6318
  • HSDB 8204
  • HY-10284
  • J-519354
  • JENTADUETO COMPONENT OF LINAGLIPTIN
  • LINAGLIPTIN COMPONENT OF GLYXAMBI
  • LINAGLIPTIN COMPONENT OF JENTADUETO
  • LINAGLIPTIN COMPONENT OF TRIJARDY XR
  • Linagliptin
  • Linagliptin (BI-1356)
  • Linagliptin (JAN/USAN/INN)
  • Linagliptin; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
  • Linaglitpin
  • MFCD14635356
  • MLS006010217
  • NCGC00346655-01
  • NCGC00346655-02
  • Ondero
  • Q909745
  • SMR004701306
  • SW219813-1
  • TRIJARDY XR COMPONENT LINAGLIPTIN
  • Tradjenta
  • Trajenta
  • Trazenta
  • ione
  • s3031

Reference codes for other databases

There exist several different chemical codes commonly used in orded to identify molecules:
  • ZINC3820029
  • UNII-3X29ZEJ4R2
  • AKOS015951179
  • AKOS015995251
  • DTXSID201021653
  • CHEMBL237500
  • CHEBI:68610
  • SCHEMBL160188

Physico-Chemical properties

IUPAC name8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
Molecular formulaC18H21NO5
Molecular weight331.363
Melting point (ºC)
Boiling point (ºC)
Density (g/cm3)
Molar refractivity89.20
LogP2.5
Topological polar surface area91.2

LogP and topological polar surface area (TPSA) values were estimated using Open Babel software.

The n-octanol/water partition coeficient (Kow) data is applied in toxicology and drug research. Kow values are used, to guess the environmental fate of persistent organic pollutants. High partition coefficients values, tend to accumulate in the fatty tissue of organisms. Molecules with a log(Kow) (or LogP) greater than 5 are considered to bioaccumulate.

TPSA values are the sum of the surface area over all polar atoms or molecules, mainly oxygen and nitrogen, also including hydrogen atoms.

In medicinal chemistry, TPSA is used to assess the ability of a drug to permeabilise cells.

For molecules to penetrate the blood-brain barrier (and act on receptors in the central nervous system), TPSA values below 90 Å2 are required. Thus, molecules with a polar surface area greater than 140 Å2 tend to be poorly permeable to cell membranes.